Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 16/20 | 0.59 |
| ▸ | CA1 | P00915 | 12/20 | 0.59 |
| ▸ | CA12 | O43570 | 8/20 | 0.59 |
| ▸ | CA9 | Q16790 | 8/20 | 0.59 |
| ▸ | CA7 | P43166 | 8/20 | 0.59 |
| ▸ | CA4 | P22748 | 6/20 | 0.59 |
| ▸ | CA5A | P35218 | 6/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.59 |
| ▸ | CA6 | P23280 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639617 | 0.82 | CA2 (0.67) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL2674394 | 0.82 | CA2 (0.62) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL10972515 | 0.82 | POLB (0.47) | SMN1; SMN2KDM4ETSHR | |
| SCHEMBL2396163 | 0.82 | ENPP2 (0.50) | SMN1; SMN2KDM4E | |
| SCHEMBL6364929 | 0.81 | CA2 (0.71) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL30870631 | 0.81 | CA2 (0.60) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL16892297 | 0.80 | PSIP1 (0.57) | SMN1; SMN2 | |
| SCHEMBL11516453 | 0.80 | CA2 (0.59) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL2083561 | 0.80 | POLB (0.46) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL8403545 | 0.80 | POLB (0.61) | CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-9433594-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-8741944-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8445483-B1 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-8080574-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | SMN1; SMN2 3791/4885KDM4E 2345/4885CA2 3715/4885 |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | SMN1; SMN2 4353/4885KDM4E 1175/4885CA2 2425/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | SMN1; SMN2 3200/4885KDM4E 1103/4885CA2 2321/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | SMN1; SMN2 1388/4885KDM4E 3848/4885CA2 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.